{
    "nctId": "NCT06098599",
    "briefTitle": "Comparing the Pharmacokinetic Profile of LY01612 and CAELYX\u00ae in Chinese Subjects With Advanced Breast Cancer",
    "officialTitle": "A Multicenter, Randomized, Open-lable, Single-dose, Two-cycle, Double-cross Bioequivalence Study Comparing the Pharmacokinetic Profile of LY01612 and CAELYX\u00ae in Chinese Subjects With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "plasma maximum concentration (Cmax) of encapsulated doxorubicin.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntary agreement to provide written informed consent;\n2. Patients aged \u226518 years and \u226475 years with locally advanced or metastatic breast cancer diagnosed by histology or cytology\uff0cand who may benefit from monotherapy of Doxorubicin liposomes;\n3. Life expectancy of at least 3 months; Eastern Cooperative Oncology Group (ECOG) performance status (PS)\\<2;\n4. adequate bone marrow function \\[leukocyte \u22653,000/mm3, absolute neutrophil count (ANC) \u22651,500/mm3, hemoglobin \u226590g/L, and platelet count \u226590,000/mm3\uff1b\n5. adequate renal function (serum creatinine \u22641.5\u00d7Institutional upper limit of normal (ULN));\n6. adequate coagulation function \\[prothrombin time (PT), activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN\\];\n7. adequate hepatic function \\[aspartate aminotransferase (AST), alanine aminotransferase (ALT) level \u2264 2.5\u00d7ULN (or \u22645\u00d7ULN for subjects with liver metastases), and total bilirubin level \u2264 1.5\u00d7ULN (or \u2264 3\u00d7ULN for subjects with liver metastases).\n\nExclusion Criteria:\n\n1. Patients with a diagnosis of severe cardiovascular, lung, liver, kidney, gastrointestinal, endocrine, immune system, skin, musculoskeletal, neurological or psychiatric conditions that the researchers did not consider appropriate for inclusion;\n2. With a history of myocardial infarction, unstable angina pectoris, coronary revascularization, New York Heart Association (NYHA) grade \u2265\u2161 cardiac insufficiency, severe pericardial disease, and severe unstable ventricular arrhythmia, cerebrovascular accident or transient cerebral ischemia or pulmonary embolism within 6 months before randomization;\n3. Unstable brain metastases;\n4. Electrocardiogram (ECG) QTC \\>480ms; left ventricular ejection fraction \\<50% or below the lower limit of study center value;\n5. The total cumulative dose of doxorubicin was \ufe65350mg/m2 before screening\uff1b\n6. Persistent or active infection requiring systemic treatment;\n7. Pregnancy or breast feeding;\n8. Other situations that investigators consider as contra-indication for this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}